+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.

Age: 16Years - 80YearsAll GendersPhase 3
461 locations
P

Actively Recruiting

Researchers are studying the effects of duvakitug in adults and older teenagers with moderately to severely active Ulcerative Colitis UC, a condition causing inflammation in the colon. This Phase 3 clinical trial is designed to evaluate both the effectiveness and safety of this treatment compared to placebo injections. The study is randomized, double-blind, and takes place at multiple international centers to ensure reliable results. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The trial includes a screening period followed by a 12-week initial treatment phase, with an additional 12-week extended induction period for those who do not respond initially. Participants who do not join the maintenance study will have a 45-day follow-up visit after completing the induction phases. During the study, participants will attend up to 8 visits in the initial treatment phases and up to 15 visits if they continue to the extended induction period. Researchers will assess clinical remission rates, endoscopic improvement, symptom responses, quality of life scores, and safety outcomes such as adverse events and immune responses to the drug. The total study participation may last up to 35 weeks, allowing close monitoring of health and treatment effects throughout.

Age: 16Years - 80YearsAll GendersPhase 3
240 locations
I

Actively Recruiting

Researchers are investigating a care approach called Concordant Care to improve how Veterans with Long-COVID are treated. This approach focuses on validating the patients experience, building a shared understanding of Long-COVID, and creating personalized action plans to manage the condition. The study addresses the current lack of training for clinicians on providing this care to Veterans with poorly understood conditions like Long-COVID. The study has two parts. In Part 1, researchers will adapt and refine Concordant Care training through interviews and focus groups with Veterans and primary care providers. In Part 2, a randomized trial will compare clinicians receiving Concordant Care training to those receiving an education packet about Long-COVID. Clinicians in the training group will complete online modules, participate in tele-mentoring sessions, receive reminder tools, and Veterans will get prompts to discuss their Long-COVID with their clinicians. Veterans participating in the study will complete assessments before and about three months after their appointments with participating clinicians. Researchers will evaluate changes in clinicians use of recommended care practices and Veterans perceptions of shared understanding. They will also measure patient satisfaction, adherence to care, and disability related to Long-COVID. The study will monitor outcomes over this timeframe to explore the effectiveness of Concordant Care training.

All AgesAll GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are studying how to best monitor pancreatic cysts and identify biomarkers that may signal the risk of these cysts developing into pancreatic cancer. The study compares two different monitoring approaches with varying frequencies, aiming to learn which method and biomarkers help improve patient outcomes. This observational study focuses on adults aged 50 to 75 who have pancreatic cysts detected by imaging. Participants undergo either low-intensity or high-intensity surveillance programs. The low-intensity group receives MRI, CT, or endoscopic ultrasound EUS scans initially and at intervals up to every two years depending on findings. The high-intensity group has more frequent imaging based on cyst size, including regular MRI, CT, and EUS scans. Blood samples, biopsies, and fine-needle aspirations may also be collected as needed. The study follows patients for 5 years from enrollment. During the trial, participants have regular imaging tests such as MRI, CT, and EUS, along with blood sample collections to assess biomarkers related to cyst changes. Researchers monitor clinical outcomes including the development of worrisome or high-risk features, quality of life, anxiety, financial distress, and healthcare costs. The study also tracks adherence to surveillance and surgical outcomes. Follow-up continues for 5 years to capture long-term results and identify factors linked to pancreatic cyst progression.

Age: 50Years - 75YearsAll Genders
429 locations
S

Actively Recruiting

Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.

Age: 40Years - 80YearsAll GendersPhase 3
314 locations
C

Actively Recruiting

This research aims to compare the impact of Exposure and Response Prevention ERP therapy versus a stress management training control on Veterans with Obsessive Compulsive Disorder OCD, including those with both OCD and posttraumatic stress disorder PTSD. The study will evaluate how these treatments affect Veterans functioning, quality of life, and OCD symptoms. Additionally, the study will explore the potential for implementing ERP in Veterans Affairs VA mental health settings through mixed-methods evaluation. Participants will be randomly assigned to receive either 16 weekly sessions of ERP or 16 weekly sessions of stress management training, both delivered via video telehealth VTH. ERP sessions, lasting 90 minutes each, involve psychoeducation, assessment, exposures to feared situations, and homework assignments focused on coping with OCD triggers. Stress management training includes psychoeducation and sessions teaching relaxation and coping skills. Assessments will be conducted after treatment and six months later. ERP participants will also provide feedback on treatment satisfaction and participate in qualitative interviews. Veterans will be involved in completing assessments of their work and social adjustment, quality of life, and OCD symptoms at baseline, post-treatment, and six months post-treatment. Researchers will collect data on treatment effects and implementation potential. Therapy sessions will be audio-recorded. The total participation lasts through treatment and follow-up visits up to six months after treatment completion.

Age: 18Years +All GendersPhase Not Applicable
19 locations
S

Actively Recruiting

Researchers are investigating whether N-Acetyl Cysteine NAC can reduce chronic oxidative stress and restore antioxidant levels in veterans with Gulf War Illness GWI. This study focuses on understanding how NAC affects mitochondrial function and oxidative stress in the central nervous system CNS, which are believed to contribute to the symptoms of GWI such as fatigue, pain, and neurological issues. The study is an early-phase, randomized, placebo-controlled trial aimed at exploring NACs impact on serum glutathione levels and CNS oxidative stress. Participants will be randomly assigned to receive either NAC 900 mg twice daily or a matching placebo for 8 weeks. The intervention is designed to assess NACs ability to target mitochondrial dysfunction and oxidative stress compared to placebo. The study includes a follow-up period extending to 16 weeks to monitor treatment-related adverse events and changes in glutathione levels. During the study, participants will undergo blood specimen collection and neuroimaging to measure glutathione levels and oxidative stress markers. Researchers will evaluate these markers from baseline through 8 weeks of treatment, with additional safety monitoring up to 16 weeks. Participants will be required to attend follow-up visits and provide written consent, with the total study duration covering the treatment and observation periods.

Age: 47Years - 70YearsAll GendersEarly Phase 1
7 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations